Dexmedetomidine, an α-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion

J Thorac Cardiovasc Surg. 2014 Jan;147(1):500-6. doi: 10.1016/j.jtcvs.2013.07.043. Epub 2013 Sep 13.

Abstract

Objective: Dexmedetomidine, an α-2a adrenergic agonist, given pre- and postoperatively was previously shown to attenuate neuronal injury in a murine model of spinal cord ischemia-reperfusion. In the brain, α-2 agonists have been shown to induce the phosphorylation of cyclic AMP response-element binding protein (CREB), a transcription factor necessary for neuron survival. We hypothesized that the α-2a adrenergic agonist given preoperatively increases CREB-mediated neuroprotective proteins, attenuating neuronal injury and cytoarchitectural decay.

Methods: Mice (ie, C57BL/6 mice) underwent 5 minutes of aortic occlusion via median sternotomy. Mice received 25 μg/kg dexmedetomidine or equivalent normal saline at 24 hours, 12 hours, and 30 minutes preoperatively. Functional outcomes were recorded at 6 to 48 hours postoperatively when spinal cords were removed for histologic analysis. Spinal cords were examined for protein kinase B, CREB, B-cell lymphoma 2, and brain-derived neurotrophic factor following treatment alone or ischemia-reperfusion surgery.

Results: Following aortic occlusion, mice in the treatment group had preserved neurologic function at all time points (P < .05). Histologic analysis showed preserved cytoarchitecture and decreased neuronal injury in the treatment group when compared with ischemic controls. Additionally, analysis of spinal cord homogenate following surgery and pretreatment revealed a significant (P < .05) increase in B-cell lymphoma 2 and brain-derived neurotrophic factor expression and protein kinase B and CREB phosphorylation with α-2a adrenergic agonist pretreatment.

Conclusions: Pretreatment with the α-2a agonist dexmedetomidine preserved neurologic function and attenuated neuronal injury following thoracic aortic occlusion in mice. This relationship was associated with an increased phosphorylation of protein kinase B and CREB and subsequent up-regulation of antiapoptotic factor B-cell lymphoma 2 and brain-derived neurotrophic factor. Thus, α-2a receptor agonism-induced CREB phosphorylation and contributes to dexmedetomidine's protective mechanism in the spinal cord following ischemia.

Keywords: 26.1; 38; 38.1; B-cell lymphoma 2; BCL-2; BDNF; CREB; IR; PBS; brain-derived neurotrophic factor; cyclic AMP response-element binding protein; ischemia-reperfusion; phosphate buffered saline.

MeSH terms

  • Adrenergic alpha-2 Receptor Agonists / pharmacology*
  • Animals
  • Aorta, Thoracic / surgery
  • Brain-Derived Neurotrophic Factor / metabolism
  • CREB-Binding Protein / metabolism
  • Constriction
  • Dexmedetomidine / pharmacology*
  • Disease Models, Animal
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology*
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Receptors, Adrenergic, alpha-2 / drug effects*
  • Receptors, Adrenergic, alpha-2 / metabolism
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Signal Transduction / drug effects
  • Spinal Cord / drug effects*
  • Spinal Cord / metabolism
  • Spinal Cord / pathology
  • Spinal Cord Ischemia / metabolism
  • Spinal Cord Ischemia / pathology
  • Spinal Cord Ischemia / therapy*
  • Time Factors

Substances

  • Adra2a protein, mouse
  • Adrenergic alpha-2 Receptor Agonists
  • Brain-Derived Neurotrophic Factor
  • Neuroprotective Agents
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Adrenergic, alpha-2
  • Bcl2 protein, mouse
  • Dexmedetomidine
  • CREB-Binding Protein
  • Crebbp protein, mouse
  • Proto-Oncogene Proteins c-akt